Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the
inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is …

The clinical penetrance of venous thromboembolism (VTE) susceptibility genes is variable,
being lower in heterozygous carriers of factor V Leiden and prothrombin 20210A (mild …

Introduction Natural anticoagulants deficiency (antithrombin [AT], protein C [PC], protein S
[PS]) is a rare, but potent risk factor for venous thromboembolism (VTE). We performed a …

Few data are available on the risk of recurrent venous thromboembolism (VTE) associated
with the rare inherited deficiencies of natural anticoagulants. We studied 602 patients with …

In thrombophilic families, protein S deficiency is clearly associated with venous thrombosis.
We aimed to determine whether the same holds true in a population-based case-control …

Objectives The aim of this study was to investigate the effect of management on the risk for
recurrent events among patients with cryptogenic ischemic stroke or transient ischemic …

Antithrombin deficiency is a strong risk factor for venous thromboembolism (VTE), but the
absolute risk of the first and recurrent VTE is unclear. The objective of this paper is to …

Evaluation for underlying hypercoagulable states in patients with thrombosis is a frequent
clinical conundrum. Testing for thrombophilias is often reflexively performed without strategic …

OBJECTIVE: This review was performed to analyze the current knowledge and
controversies in the pathophysiology, diagnosis, treatment, and outcomes of pediatric …

Background Thrombophilia screening is widely done in clinical practice, and it is claimed
that the extent of venous thromboembolism (VTE) recurrence risk in patients with common …